Amgen to obtain Onyx Pharmaceuticals for $125 per share in cash Amgen and Onyx Pharmaceuticals

Amgen to obtain Onyx Pharmaceuticals for $125 per share in cash Amgen and Onyx Pharmaceuticals, Inc . announced that their Boards of Directors possess unanimously approved a deal under which Amgen will acquire all of the exceptional shares of Onyx for $125 per talk about in cash. The purchase price is definitely $10.4 billion, or $9.7 billion net of estimated Onyx cash. Onyx Pharmaceuticals, Inc. Is a global biopharmaceutical company engaged in the advancement and commercialization of innovative therapies for enhancing the lives of people with cancer.S.). Compound). Onyx has multiple oncology compounds in various stages of clinical development also. Amgen intends to impact the deal through a tender give and expects to close at the beginning of the fourth one fourth, subject to the satisfaction of customary closing circumstances, including the receipt of regulatory clearance. ‘We believe that Amgen is ideally suited to realize the entire potential of Onyx’s portfolio and pipeline for the benefit of physicians and individuals,’ stated Robert A. Bradway, chairman and ceo at Amgen. ‘Our acquisition of Onyx follows a thorough due diligence process and is completely consistent with our technique of advancing innovative medicines that address serious unmet medical needs. We anticipate this acquisition will accelerate development and enhance worth for Amgen shareholders. ‘Amgen has a unique opportunity to add worth to Kyprolis, a product which is at an promising and early stage of its start,’ Bradway continued. Keeps global privileges to Kyprolis Onyx, excluding Japan. Kyprolis comes with an orphan medication designation in the U.S. Until July 2019 with exclusivity, and patents in the U.S. Which prolong until at least 2025. Amgen will benefit from the global rights to Onyx’s innovative oncology portfolio and pipeline. Amgen intends to leverage its oncology capabilities and experience to support Onyx’s clinical development programs and increase Kyprolis’ potential in the U.S. And the rest of the world. The acquisition of Onyx also increases Amgen’s robust late-stage pipeline. This pipeline includes nine innovative products that registration-enabling data are anticipated by 2016. Four of the are innovative, first-in course oncology products. Onyx’s pipeline complements Amgen’s growing oncology portfolio. Furthermore to accelerating Amgen’s income development, the acquisition of Onyx is normally expected to become accretive to Amgen’s altered net gain in 2015. ‘After a careful and comprehensive evaluation process, our Board of Directors has established that the all-cash transaction with Amgen maximizes worth for our stockholders and expands the potential of our commercial medicines and medical pipeline to attain more sufferers globally,’ stated Dr. Tony Coles, chairman and ceo of Onyx. Coles continuing, ‘We are pleased to have reached this agreement with Amgen, a organization that shares Onyx’s vision for innovation on behalf of patients. This transaction is an important affirmation of the meaningful value our employees have created, and we look forward to rewarding our stockholders with an attractive and immediate high quality.’ Bradway concluded, ‘Our two companies share a strong culture of technology and a concentrate on patient requirements. I anticipate bringing the talented people of Onyx and Amgen together as we continue to fulfill our commitment to unlocking the potential of biology for individuals suffering from serious ailments.’ About Amgen Amgen is certainly focused on unlocking the potential of biology for individuals suffering from serious illnesses by discovering, developing, manufacturing and providing innovative human therapeutics. This process begins by using tools like advanced human being genetics to unravel the complexities of disease and understand the basics of human being biology. Amgen focuses on regions of high unmet medical need and leverages its biologics making expertise to shoot for solutions that improve wellness outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to end up being the world’s largest independent biotechnology organization, has reached millions of individuals around the global globe and is creating a pipeline of medicines with breakaway potential. About Onyx Located in South SAN FRANCISCO BAY AREA, California, Onyx Pharmaceuticals, Inc. Is a global biopharmaceutical company engaged in the advancement and commercialization of innovative therapies for improving the lives of people with cancer. The company is targeted on developing novel medicines that target key molecular pathways.

revatio tablets

Amherst neurobiologists awarded grant to study how neurons regulate locomotion Neurobiologist Gerald Downes, with chemist James Chambers in the University of Massachusetts Amherst and Amherst College neurobiologist Josef Trapani, have been awarded a three-year $824,025 collaborative research grant from the National Technology Foundation to study the zebrafish mind to better understand how neurons regulate locomotion. Downes, the business lead investigator, says his ultimate research objective is to better understand how different chemical signals, called neurotransmitters, work together at cellular and molecular levels to coordinate normal locomotion such as for example swimming and walking. Downes says the grant may also support his intend to provide neuroscience demonstrations to as much as 600 Springfield and Holyoke charter middle and high school students within their science classes from spring 2016, accompanied by visits to UMass Amherst. Participating schools are the Renaissance Charter College in Springfield and Paolo Frieri Social Justice High School in Holyoke. ‘This is a significant aspect of the grant to me,’ he says. ‘I believe in calling young students, from disadvantaged backgrounds particularly, to show them who scientists are and what we perform. Hopefully we will help inspire some college students to pursue careers in science.’ As the neurobiologist clarifies, locomotion can be done because human brain cells, or neurons, talk to one another using the neurotransmitters. In the mind's neuronal networks, signals pass from one neuron to another, then to neurons in the spinal-cord, which complete signals to muscles finally. ‘Some neurotransmitters boost neuron activity whereas others decrease neuron activity. We're working to tease away cellular and molecular mechanisms of brain circuitry that control motion,’ he offers. ‘And because there are plenty of similarities in neurotransmitters and locomotor systems between zebrafish and mammals, this ongoing work can have implications about locomotion in lots of species, including human beings.’ Zebrafish have a far more simple mind and spinal cord than mammals and their embryos are transparent, making them easy to examine under a microscope, the neurobiologist highlights. For this project the researchers will focus on how one neurotransmitter referred to as gamma aminobutyric acid type A regulates locomotor networks in the brain. Related StoriesBrain wellness: how can you reduce cognitive decline? An interview with Heather Snyder, Ph.D.Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. KlegermanResearchers discover potential new way to focus on brain cells suffering from Parkinson's diseaseDownes explains, ‘Area of the difficulty in understanding how these neuronal systems function is there are a wide variety of GABA receptors, which allow neurons to receive GABA signals. So a main goal of this project is to recognize individual types of GABA receptors that are essential for locomotion.’ To do this, the team will use a number of approaches relating to the mutation of different GABA receptors and examining the consequences such mutations possess on locomotion. Trapani's lab shall investigate how mutations change the electrical activity of individual neurons involved with locomotion, for example. In addition, the team will use drugs developed by Chambers that bind to GABA receptors and block their function with respect to the wavelength of light. GABA binding to a receptor could be blocked using one wavelength of light, however, not using a different one, Downes clarifies. The transparency of the zebrafish embryo makes them great for this optical strategy, he adds. ‘Using light, we will be able to turn on and turn off various kinds of GABA receptors on different cell types,’ Downes says, ‘and observe how that effects locomotion.’ ‘We're thrilled to gather our different regions of experience to tackle such a complex but interesting problem. Challenging new technology now available, it's an enjoyable experience to be a neuroscientist.’ The project also includes a training element that will support UMass Amherst alumna Kelly Anne McKeown, associate professor of biology at Westfield State University, and two of her college students to conduct summer study in neuroscience using state-of-the-art laboratory instruments and techniques in the Downes laboratory.